• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Chair: Tina WONG (Singapore)

Date & Time: Saturday, 25 July 2026, 1245 – 1345 hrs         Venue: Level 4, Hall 406CX

This “ROCK the Bar” symposium will explore the role of the Rho kinase (ROCK) inhibitor in glaucoma management. A panel of leading experts from Asia will discuss how netarsudil targets both the proximal and distal regions of the trabecular meshwork, share regional real-world experience with Rhopressa (netarsudil) and Rocklatan (netarsudil/latanoprost fixed-dose combination), and lead an interactive discussion on integrating these therapies into routine clinical practice.

Time Presentation Topic Speaker
1245 – 1250 Welcome Tina WONG
Singapore
1250 – 1300 Targeting the Entire Outflow Journey: TM, Uveoscleral, and EVP Shan LIM
USA
1300 – 1310 Real-world Experience with Rhopressa: A Flexible Add-on at Any Stage Chungkwon YOO
South Korea
1310 – 1320 Real-world Experience with Rocklatan: Leveraging Triple-pathway Outflow Management Bryan ANG
Singapore
1320 – 1340 Expert Panel Discussion: Are You Ready to ROCK the Bar in Glaucoma Care? All Faculty
1340 – 1345 Summary and Closing Tina WONG
Singapore

Abstract submission deadline extended

Important dates
Good News! Abstract Submission Now Open Until 21 February 2026